Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Explore how Zero-Based Budgeting can outperform Incremental Budgeting by prioritizing needs, justifying every expense, and improving efficiency.
25,905 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Apple doubles down on returning capital to shareholders with a $100 billion buyback and a dividend hike, while rivals...
A new wave of AI-enabled lending could be headed for auto loans. This article explains why upstart's auto loan push m...
Two AI-focused giants sit at the crossroads of growth and scale. This guide breaks down Palantir and Oracle through r...
BlackRock’s chief executive argues that AI’s biggest impact is on who owns wealth, not just who loses a job. Here’s h...
If SpaceX shifts a sizable slice of its IPO to everyday investors, the market could see bigger demand and new pricing...
Retiring executives with sizable employer stock in their 401(k) are increasingly using Net Unrealized Appreciation to...
Stablecoins are moving to the heart of international money movement. As these digital dollars promise speed and lower...
DexCom and Insulet sit at the heart of diabetes technology. This in-depth look examines growth drivers, financials, a...
A rising chorus of planners argues the fixed 4% rule may trap retirees in unnecessary caution. Experts say flexible w...
Burger King is piloting OpenAI-powered headsets in 500 U.S. locations to boost efficiency and coaching. The program c...
Emerging renders point to a major Siri refresh: a standalone app, deeper Dynamic Island integration, and a Gemini-bas...